Actively Recruiting

Early Phase 1
Age: 4Years - 8Years
MALE
NCT06641895

Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy

Led by Shanghai Jiao Tong University School of Medicine · Updated on 2025-03-25

6

Participants Needed

1

Research Sites

313 weeks

Total Duration

On this page

Sponsors

S

Shanghai Jiao Tong University School of Medicine

Lead Sponsor

S

Shanghai Mianyi Biopharmaceutical Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of the study is to assess the safety, tolerability, and efficacy of BBM-D101 to treat patients with Duchenne Muscular Dystrophy.

CONDITIONS

Official Title

Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy

Who Can Participate

Age: 4Years - 8Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • The legal guardian understands the study and signs informed consent
  • Ambulatory male subjects aged at least 4 years and less than 8 years
  • Genetically confirmed diagnosis of Duchenne Muscular Dystrophy
  • Presence of clinical signs or lab abnormalities typical of DMD such as proximal muscle weakness, waddling gait, pseudo gastrocnemius hypertrophy, Gower's sign, or pterygoid scapula
  • Ability to cooperate with motor assessments, MRI, and muscle biopsy as required by the study
Not Eligible

You will not qualify if you...

  • Positive for hepatitis B surface antigen, hepatitis B virus DNA ≥1000 U/mL, hepatitis C virus RNA positive, or HIV positive
  • Receiving antiviral treatment for hepatitis B, hepatitis C, or HIV
  • Left ventricular ejection fraction less than 50% or class III or higher cardiac function by NYHA
  • Severe or persistent arrhythmias or congenital heart disease
  • Changes in preventive or cardiomyopathy treatment within 1 month before study treatment
  • Underlying liver disease such as portal hypertension, splenomegaly, hepatic encephalopathy, or stage 3 or higher hepatic fibrosis, or liver nodules/cysts or elevated alpha-fetoprotein judged clinically significant

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China, 200127

Actively Recruiting

Loading map...

Research Team

J

Jiwen Wang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy | DecenTrialz